G6PD and myeloid sarcoma: G6PD level in patients with MS with consumption of vitamin D history was higher compared to patients with MS not treated by vitamin D (18.550 ± 2.762 vs. 16.465 ± 1.290) (P < 0.05), but still well below the level in the healthy group (18.550 ± 2.762 vs. 82.185 ± 7.867) (P < 0.001) (Figure 1).